Cytopoint is a monoclonal antibody therapy approved by the USDA to help provide sustained control of the clinical signs associated with atopic dermatitis and allergic dermatitis in dogs. Cytopoint targets and neutralizes interleukin-31 (IL-31), a key protein involved in triggering itch in dogs. It provides fast relief of itching and offers the sustained efficacy and convenience of one injection every four to eight weeks. Cytopoint helps improve the long-term quality of life for dogs suffering from atopic dermatitis and eases the frustration and concern of their owners. It is now available to all veterinarians in the United States. For fastest response visit cytopoint.com.